RENAL TRANSPLANTATION IN CROSSMATCH POSITIVE RECIPIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 供者特异性抗体的存在是器官移植的一个重要障碍，因为存在发生超急性排斥反应或加速排斥反应的风险，导致移植物丢失。UNOS登记表明，致敏患者的平均等待时间是未致敏患者的两倍多，有些人可能永远不会接受移植。这项研究的目的是通过研究由IVIG、霉酚酸酯(MMF)和利妥昔单抗组成的预治疗方案来降低这些患者的致敏水平，以使交叉配型阳性的患者脱敏，并使选择有限的患者能够成功地进行活体供肾移植。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The presence of donor-specific antibodies present a significant barrier to organ transplantation due the risk for development of hyperacute or accelerated rejection leading to graft loss. UNOS registry demonstrates that the average waiting time of sensitized patients is more than twice those who are not sensitized and some may never receive a transplant. The aim of this study is to decrease the sensitization level of these patients by studying a pre-treatment regimen consisting of IVIG, Mycophenolate Mofetil (MMF), and Rituximab to desensitize patients with positive crossmatches and allow successful living donor renal transplantation in patients who have limited options.